Washington University in St. Louis

NEW BELGIUM BREWING ANNOUNCES SHAUN BELONGIE AS NEW CHIEF EXECUTIVE OFFICER

Retrieved on: 
Mittwoch, November 8, 2023
Lion Group, New Belgium Brewing Company, Oberon, Washington University in St. Louis, Beer, Bell's Brewery, Bell, Carbon, MBA, Believer, Triple accreditation, Business, Nestlé Purina PetCare, Interim, Pleasure, Marquette University, Kraft Foods, Bachelor of Arts, Belgium, La Folie, Management, New Belgium, Serge Belongie

FORT COLLINS, Colo., Nov. 8, 2023 /PRNewswire/ -- Today, New Belgium Brewing announced that Shaun Belongie, New Belgium's Chief Marketing Officer of 5 years, will become its next Chief Executive Officer and lead the business into its next chapter as a trailblazer in the beer industry while continuing to strengthen its human-powered business practices. 

Key Points: 
  • FORT COLLINS, Colo., Nov. 8, 2023 /PRNewswire/ -- Today, New Belgium Brewing announced that Shaun Belongie, New Belgium's Chief Marketing Officer of 5 years, will become its next Chief Executive Officer and lead the business into its next chapter as a trailblazer in the beer industry while continuing to strengthen its human-powered business practices.
  • "New Belgium Brewing is a special place, powered by the best people in the business.
  • "We are delighted to welcome Shaun as the next CEO of New Belgium," said Sam Fischer.
  • Belongie will step in the CEO role immediately, and the organization will be sharing details in the near future on plans for filling the vacant Chief Marketing Officer role.

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Retrieved on: 
Mittwoch, November 8, 2023
Radiation therapy, Standard of care, DOTATATE, NYSE, Washington University in St. Louis, CATX, European Association of Nuclear Medicine, Mallinckrodt Institute of Radiology, PRRT, Glomus tumor, Tissue, Washington University School of Medicine, SSTR2, European Association for the Study of the Liver, NETS, TAT, Safety, Fast track (FDA), Therapy, Patient, Pharmaceutical industry, Radiology

The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).

Key Points: 
  • The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).
  • “We are proud of our team’s commitment and progress in bringing our radionuclide therapy to patients suffering from these difficult-to-treat neuroendocrine tumors,” said Thijs Spoor, Chief Executive Officer of Perspective Therapeutics.
  • “The development of Perspective’s [212Pb]VMT-α-NET targeted alpha particle therapy is an important next step in the evolution of treatments for SSTR2-expressing tumors.
  • We are excited to participate in the trial.”
    “We are excited about our collaboration with investigators from top-tier research centers who are evaluating [212Pb]VMT-α-NET in patients with intractable SSTR2-expressing neuroendocrine tumors,” said Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics.

Massage Replaces Invasive Surgeries

Retrieved on: 
Dienstag, November 7, 2023
Female, Adhesion, Fallopian tube, Publishing, Washington University in St. Louis, Physician, Massage, Research, Harvard University, Clear, Medicine, Surgeon, Recurrence, Scientific method, Stanford University, Bowel obstruction, Woman, Tubing (recreation), Diagnosis, Infertility, Birth control, Dentistry, Dietary supplement, U.S.A

GAINESVILLE, Fla., Nov. 7, 2023 /PRNewswire/ -- A 'hands-on' therapy that can feel like a deep massage has replaced major surgeries in two fields of medicine: female infertility and serious digestive problems per researchers at Clear Passage® Therapies. Following decades of research, studies show the therapy has opened totally blocked fallopian tubes in dozens of women, a procedure once thought impossible without surgery. In a controlled study co-authored by independent surgeons, the therapy cleared and decreased life-threatening bowel obstructions, obviating a common emergency surgery.

Key Points: 
  • In a controlled study co-authored by independent surgeons, the therapy cleared and decreased life-threatening bowel obstructions, obviating a common emergency surgery.
  • "Doctors refused to operate again saying that would make matters worse by creating more glue-like adhesions.
  • My husband Larry became a massage therapist.
  • Applicants complete a Medical History Form which Clear Passage® reviews at no charge to determine appropriateness and likelihood of success.

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Montag, November 6, 2023
Janus, Research, Lilly, Eli Lilly and Company, AD, Plasma, Half-life, PD, Psoriatic arthritis, Washington University in St. Louis, Biomarker, JAK3, EPI, G&A, Health, Rheumatoid arthritis, MAD, JAK, R, RA, ITK, ACRS, Ulcerative colitis, Osteoporosis, Pharmacokinetics, Hidradenitis suppurativa, PK, Methotrexate, Pancreatic cancer, Safety, Atopic dermatitis, Collection, Chapter 11, Title 11, United States Code, Therapy, Patient, MK2, Pharmaceutical industry, Vaccine, Palladium, Cryptocurrency, Rare-earth element, Tobacco, Hydraulic machinery

WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2023 and provided a corporate update.

Key Points: 
  • Net loss was $29.3 million for the third quarter of 2023 compared to $20.0 million for the third quarter of 2022.
  • Total revenue was $9.3 million for the third quarter of 2023 compared to $19.0 million for the third quarter of 2022.
  • Research and development (R&D) expenses were $23.9 million for the quarter ended September 30, 2023 compared to $23.7 million for the prior year period.
  • General and administrative (G&A) expenses were $7.1 million for the quarter ended September 30, 2023 compared to $5.8 million for the corresponding prior year period.

Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition

Retrieved on: 
Donnerstag, November 2, 2023
Marriott Marquis, Patient, University of Nottingham, Washington University in St. Louis, Lymphoma, Intel Extreme Masters, Society, ASH, LBL, San Diego Marriott Marquis & Marina, NK, Abstract, Cell therapy, Exposition, Safety, American Society for Investigative Pathology, AML, SAN, Pharmaceutical industry, Vaccine, Mobile phone, Leukemia

ST. LOUIS and SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, will be presenting four abstracts, now available online, at the American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 9-12.

Key Points: 
  • The Wugen oral and poster presentation schedule at ASH is below.
  • The meeting will take place at the Marriott Marquis in San Diego and virtually.
  • Access the full schedule here .
  • Session: #704, Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas, 10:30 a.m.- 12 p.m. PT
    Session: #703, Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies, 9:30-11 a.m. PT

Foundation for Sarcoidosis Research Announces 3 New Members to the 40 Member FSR Global Sarcoidosis Clinic Alliance through its FSR-GSCA Capacity Building Grants

Retrieved on: 
Mittwoch, November 1, 2023
Rheumatology, Science, Research, Sarcoidosis, Education, Health, Washington University in St. Louis, Family, Rational ignorance, Critical care, New Jersey Medical School, Critical Care Medicine (journal), FSR, Division, Clinical trial, Hospital, Overalls, Patient, Health system, Associate, Pharmaceutical industry, Nursing, Rutgers University

FSR is dedicated to advancing the needs of all patients impacted with sarcoidosis and to closing the health care disparities gap that affects our community.

Key Points: 
  • FSR is dedicated to advancing the needs of all patients impacted with sarcoidosis and to closing the health care disparities gap that affects our community.
  • These capacity building grant recipients completed a competitive application process and have been awarded a complimentary 1-year membership (valued at $5,000) in the FSR-GSCA.
  • “Washington University is honored to become a member of the FSR Global Sarcoidosis Clinical Alliance.
  • "FSR is honored to have these three prestigious institutions join our extraordinary group of FSR Global Sarcoidosis Clinic Alliance members.

Apogee Hires Defense Industry Finance Expert Andrew Cox as New CFO

Retrieved on: 
Montag, November 6, 2023
Science, University of Colorado Student Government, Mathematics, Washington University in St. Louis, Parsons Corporation, Apsis, MBA, Cox, Growth, Trump Media & Technology Group, University, Eye, CFO, Colorado Springs, Colorado, Western Washington University, Management

COLORADO SPRINGS, Colo., Nov. 6, 2023 /PRNewswire/ -- Apogee, a leading defense and security solutions provider, has appointed a new chief financial officer (CFO) Andrew Cox, a two-decade finance veteran in the defense industry effective October 16, 2023.

Key Points: 
  • COLORADO SPRINGS, Colo., Nov. 6, 2023 /PRNewswire/ -- Apogee, a leading defense and security solutions provider, has appointed a new chief financial officer (CFO) Andrew Cox, a two-decade finance veteran in the defense industry effective October 16, 2023.
  • CEO and chairman Wes Georges announced this strategic appointment adding, Cox will work diligently with Apogee's leadership to further drive the company's transformative growth.
  • As CFO, Cox will oversee Apogee's finance and accounting functions with a focus on strategic execution.
  • Before working for Parsons Corporation, Cox was the vice president of finance at Braxton Science & Technology Group and CFO at TechWise.

Lynn Mason Appointed Chief Executive Officer for IVI RMA America

Retrieved on: 
Mittwoch, November 1, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Health Technology, Fertility, Woman, Disability studies, RMA, Washington University in St. Louis, Service, Physician, BSBA, 1998 Harvard vs. Stanford women's basketball game, MBA, Multimedia, DaVita Inc., American Heart, Growth, IVI, Shoe, Medical diagnosis, Business, Association of Latino Professionals in Finance and Accounting, Mason, Chenming Hu, Culture, Reproductive medicine, Patient, Gloucestershire Care Services NHS Trust, DSM-IV codes, Accounting, Management

IVI RMA America, the North American business of IVI RMA, the largest reproductive medicine group in the world, today announced the appointment of Lynn Mason as Chief Executive Officer.

Key Points: 
  • IVI RMA America, the North American business of IVI RMA, the largest reproductive medicine group in the world, today announced the appointment of Lynn Mason as Chief Executive Officer.
  • Mason currently serves on the Boards of Directors of nonprofits Shoes-That-Fit and the American Heart Association-Go Red for Women.
  • “IVI RMA has a stellar reputation for the industry’s best outcomes, most innovative R&D platform, and sharpest talent, and I am thrilled and honored to join as CEO for America,” said Mason.
  • “I’m eager to support our physician leaders in expanding our presence and strengthening our culture to make IVI RMA America the natural first choice for patients, physicians, and medical partners.”
    “The team and I look forward to Lynn bringing a fresh and energized perspective to our business and complementing our scientific leaders,” added Thomas A. Molinaro, M.D., Medical Director, IVI RMA America.

Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation

Retrieved on: 
Donnerstag, November 2, 2023
Multiple myeloma, CAR, Icahn Genomics Institute, Black, Associate, Washington University in St. Louis, Therapy, CRISPR, Genetics, Bone marrow, Icahn School of Medicine at Mount Sinai, Early Prostate Cancer (clinical programme), Translational research, Doctor of Philosophy, Multiple Myeloma Research Foundation, Research, MAC, Stanford University Medical Center, Mount Sinai Health System, University of California, San Francisco, Genomics, Growth, Disease, MMRF, Immunotherapy, University, Gene, Hackensack University Medical Center, San Francisco, Cancer, Patient, Marc, Pharmaceutical industry, Vaccine, MD

NEW YORK, Nov. 2, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.

Key Points: 
  • Multiple myeloma is a blood cancer that develops in the bone marrow and can spread throughout the body.
  • In 2023, more than 35,000 Americans are projected to be diagnosed with multiple myeloma and approximately 12,000 will lose their lives.
  • Researchers hope to uncover the full landscape of genomic, proteomic and immune differences between high- and standard-risk multiple myeloma patients.
  • "The three exciting programs we selected each have potential to answer fundamental questions about multiple myeloma and help advance rational treatments for this cancer."

Poets&Quants Releases 5th Annual Ranking of the Top MBA Programs for Entrepreneurship

Retrieved on: 
Donnerstag, November 2, 2023
Olin, Olin Business School, Entrepreneurship, Berlin, European, Clemson, Student, MBA, School, Washington University in St. Louis, Management, European School of Management and Technology

 OAKLAND, Calif., Nov. 2, 2023 /PRNewswire/ -- Poets&Quants, the definitive online publication for business education news, has unveiled its fifth annual ranking of the World's Best MBA Programs for Entrepreneurship. The data reveal that, for the fifth year in a row, the Olin Business School at Washington University in St. Louis is the world's No. 1 business school for entrepreneurship. Poets&Quants' ranking captures a wide range of criteria about U.S. and global business schools, including a school's accelerator space, venture funds available, and core classes dedicated to entrepreneurship. This year's list contained 28 schools. Our methodology is designed to measure how resources are allocated to individual students. We use percentages and ratios to get a sense of what entrepreneurial resources and experiences are like on a per MBA basis. Olin is followed by a school brand new to the ranking this year, ESMT Berlin – one of four European MBA programs to crack the top 10. 

Key Points: 
  • OAKLAND, Calif., Nov. 2, 2023 /PRNewswire/ -- Poets&Quants, the definitive online publication for business education news, has unveiled its fifth annual ranking of the World's Best MBA Programs for Entrepreneurship .
  • Olin is followed by a school brand new to the ranking this year, ESMT Berlin – one of four European MBA programs to crack the top 10.
  • "The entire ranking is filled with schools that are approaching entrepreneurship teaching in unique, interesting, and effective ways.," says Kristy Bleizeffer, lead editor of the entrepreneurship ranking.
  • The Top 10 MBA programs for entrepreneurship in 2024 are: